Skip to main content
Log in

The Medical Dictionary for Regulatory Activities (MedDRA)

  • Leading Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

The International Conference on Harmonisation has agreed upon the structure and content of the Medical Dictionary for Regulatory Activities (MedDRA) version 2.0 which should become available in the early part of 1999.

This medical terminology is intended for use in the pre- and postmarketing phases of the medicines regulatory process, covering diagnoses, symptoms and signs, adverse drug reactions and therapeutic indications, the names and qualitative results of investigations, surgical and medical procedures, and medical/social history. It can be used for recording adverse events and medical history in clinical trials, in the analysis and tabulations of data from these trials and in the expedited submission of safety data to government regulatory authorities, as well as in constructing standard product information and documentation for applications for marketing authorisation. After licensing of a medicine, it may be used in pharmacovigilance and is expected to be the preferred terminology for international electronic regulatory communication.

MedDRA is a hierarchical terminology with 5 levels and is multiaxial: terms may exist in more than 1 vertical axis, providing specificity of terms for data entry and flexibility in data retrieval. Terms in MedDRA were derived from several sources including the WHO’s adverse reaction terminology (WHO-ART), Coding Symbols for a Thesaurus of Adverse Reaction Terms (COSTART), International Classification of Diseases (ICD) 9 and ICD9-CM. It will be maintained, further developed and distributed by a Maintenance Support Services Organisation (MSSO).

It is anticipated that using MedDRA will improve the quality of data captured on databases, support effective analysis by providing clinically relevant groupings of terms and facilitate electronic communication of data, although as a new tool, users will need to invest time in gaining expertise in its use.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wood KL, Coulson RA, Wood SM. MEDDRA: the basis for the new international medical terminology for regulatory purposes. ESRA Rapporteur 1995; 2: 12–5

    Google Scholar 

  2. Mitchard M, Wood L. Regulatory communications. Eur Pharm Law Notebooks 1996; II: 139–55

    Google Scholar 

  3. Wood KL. The medical dictionary for drug regulatory affairs (MEDDRA) project. Pharmacoepidemiol Drug Saf 1994; 3: 7–13

    Article  Google Scholar 

  4. Wood KL. Rapporteur’s progress report. In: d’Arcy PFD, Harron DWG, editors. Proceedings of the Third International Conference on Harmonisation. Nov 1995, Yokahama. Belfast: Queens University Belfast Publications, 1996: 495–8

    Google Scholar 

  5. Wood KL, Wood SM. The international medical terminology for regulatory activities: a tool to improve the utilisation of regulatory data and to support its communication within and between organisations In: Mitchard M, editor. Electronic communication technologies — techniques and technologies for the 21st Century. Buffalo Grove (IL): Interpharm Press Inc., 1998: 299–332

    Google Scholar 

  6. Fescharek R, Dechert G, Reichert D, et al. Overall analysis of spontaneously reported adverse events: a worthwhile exercise or flogging a dead horse? Pharm Med 1996; 10: 71–86

    Google Scholar 

  7. Huntley K, Veverka MJ, Golden M. The FDAs medical dictionary for drug regulatory affairs alpha test. Drug Info J 1995; 29: 1133–43

    Article  Google Scholar 

  8. Brown EG, Clark E. Evaluation of MEDDRA in representing medicinal product data sheet information. Pharm Med 1996; 10: 1–8

    Google Scholar 

  9. Brown EG. Medical terminology: a view from Europe. In: D’Arcy PFD, Harron DWG, editors. Proceedings of the Third International Conference on Harmonisation. Nov 1995, Yokahama. Belfast: Queens University Belfast Publications, 1996: 500–3

    Google Scholar 

  10. Brown DR, Brown EG, Moulvad TB. A comparison of two medical terminologies in coding and analysing clinical trial safety data. Int J Pharm Med 1997; 11: 85–9

    Google Scholar 

  11. White C. Apreliminary assessment of the impact of MEDDRA on adverse event reports and product labeling. Drug Inform Assoc J 1998; 32: 347–62

    Article  Google Scholar 

  12. Tsutani K. View from Japan. In: d’Arcy PFD, Harron DWG editors. Proceedings of the Third International Conference on Harmonisation. Nov 1995, Yokahama. Belfast: Queens University Belfast Publications, 1996: 503–12

    Google Scholar 

  13. Brown EG, David M. The medical dictionary for regulatory activities (MedDRA): a survey of regulatory authority approaches to implementation. Int J Pharm Med 1998; 12: 23–7

    Google Scholar 

  14. ten Ham M. WHO and international terminology. In: d’Arcy PFD, Harron DWG, editors. Proceedings of the Third International Conference on Harmonisation. Nov 1995, Yokahama. Belfast: Queens University Belfast Publications, 1996: 514–6

    Google Scholar 

  15. MEDDRA: setting a new standard in medical terminology, [editorial]. Int J Pharm Med 1997; 11: 248

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Elliot G. Brown.

Additional information

Dr Susan Wood died suddenly in September 1998. She was director of the Post-Licensing Division of the UK Medicines Control Agency and chaired the International Conference on Harmonisation M1 Expert Working Group on medical terminology. MedDRA was conceived and came into fruition largely as a result of her vision and efforts

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brown, E.G., Wood, L. & Wood, S. The Medical Dictionary for Regulatory Activities (MedDRA). Drug-Safety 20, 109–117 (1999). https://doi.org/10.2165/00002018-199920020-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199920020-00002

Keywords

Navigation